Development of a multigenic plasmid vector for HCV DNA immunization

S. Papa, M. Rinaldi, A. Mangia, P. Parrella, E. Signori, L. Lombardi, V. M. Fazio

Research output: Contribution to journalArticle

Abstract

HCV viral nucleocapsid protein (C), non-structural protein 3 (NS3) and the envelope glycoproteins E1 and E2 are candidate immune targets for developing anti-HCV DNA vaccine. Nevertheless, the immune response elicited by these antigens often appears weak and/or transient. Different approaches have been studied for enhancing and/or modulating the immune response of the DNA vaccine. On the basis of a prototype multigenic plasmid vector constituted of two different transcription cassettes (pRC100), we have developed a plasmid vector that allows the independent and simultaneous expression of murine IL2 and of an antigenic domain of the HCV NS3 C terminus (pRC112-HCV). The highly conserved NS3 region spans from nt 4403 to nt 4829 and contains two putative B and T epitopes. The development of this multigenic plasmid vector may combine the expression and local production of an immunomodulatory molecule (mlL2) together with the possibility of addressing the host immune response to the most immunogenic and conserved epitopes, specifically tailored in the plasmid vector.

Original languageEnglish
Pages (from-to)315-319
Number of pages5
JournalResearch in Virology
Volume149
Issue number5
DOIs
Publication statusPublished - Sep 1998

Fingerprint

Immunization
Plasmids
DNA Vaccines
DNA
Protein C
Epitopes
Nucleocapsid Proteins
Histocompatibility Antigens Class II
Viral Proteins
Interleukin-2
Glycoproteins
Proteins

Keywords

  • B/T epitopes
  • DNA vaccination
  • HCV NS3
  • Multigenic plasmid vector
  • Murine lL2

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Development of a multigenic plasmid vector for HCV DNA immunization. / Papa, S.; Rinaldi, M.; Mangia, A.; Parrella, P.; Signori, E.; Lombardi, L.; Fazio, V. M.

In: Research in Virology, Vol. 149, No. 5, 09.1998, p. 315-319.

Research output: Contribution to journalArticle

Papa, S. ; Rinaldi, M. ; Mangia, A. ; Parrella, P. ; Signori, E. ; Lombardi, L. ; Fazio, V. M. / Development of a multigenic plasmid vector for HCV DNA immunization. In: Research in Virology. 1998 ; Vol. 149, No. 5. pp. 315-319.
@article{a4e088f04c9940beaf231f0389dcdf5f,
title = "Development of a multigenic plasmid vector for HCV DNA immunization",
abstract = "HCV viral nucleocapsid protein (C), non-structural protein 3 (NS3) and the envelope glycoproteins E1 and E2 are candidate immune targets for developing anti-HCV DNA vaccine. Nevertheless, the immune response elicited by these antigens often appears weak and/or transient. Different approaches have been studied for enhancing and/or modulating the immune response of the DNA vaccine. On the basis of a prototype multigenic plasmid vector constituted of two different transcription cassettes (pRC100), we have developed a plasmid vector that allows the independent and simultaneous expression of murine IL2 and of an antigenic domain of the HCV NS3 C terminus (pRC112-HCV). The highly conserved NS3 region spans from nt 4403 to nt 4829 and contains two putative B and T epitopes. The development of this multigenic plasmid vector may combine the expression and local production of an immunomodulatory molecule (mlL2) together with the possibility of addressing the host immune response to the most immunogenic and conserved epitopes, specifically tailored in the plasmid vector.",
keywords = "B/T epitopes, DNA vaccination, HCV NS3, Multigenic plasmid vector, Murine lL2",
author = "S. Papa and M. Rinaldi and A. Mangia and P. Parrella and E. Signori and L. Lombardi and Fazio, {V. M.}",
year = "1998",
month = "9",
doi = "10.1016/S0923-2516(99)89012-8",
language = "English",
volume = "149",
pages = "315--319",
journal = "Research in Virology",
issn = "0923-2516",
publisher = "Elsevier BV",
number = "5",

}

TY - JOUR

T1 - Development of a multigenic plasmid vector for HCV DNA immunization

AU - Papa, S.

AU - Rinaldi, M.

AU - Mangia, A.

AU - Parrella, P.

AU - Signori, E.

AU - Lombardi, L.

AU - Fazio, V. M.

PY - 1998/9

Y1 - 1998/9

N2 - HCV viral nucleocapsid protein (C), non-structural protein 3 (NS3) and the envelope glycoproteins E1 and E2 are candidate immune targets for developing anti-HCV DNA vaccine. Nevertheless, the immune response elicited by these antigens often appears weak and/or transient. Different approaches have been studied for enhancing and/or modulating the immune response of the DNA vaccine. On the basis of a prototype multigenic plasmid vector constituted of two different transcription cassettes (pRC100), we have developed a plasmid vector that allows the independent and simultaneous expression of murine IL2 and of an antigenic domain of the HCV NS3 C terminus (pRC112-HCV). The highly conserved NS3 region spans from nt 4403 to nt 4829 and contains two putative B and T epitopes. The development of this multigenic plasmid vector may combine the expression and local production of an immunomodulatory molecule (mlL2) together with the possibility of addressing the host immune response to the most immunogenic and conserved epitopes, specifically tailored in the plasmid vector.

AB - HCV viral nucleocapsid protein (C), non-structural protein 3 (NS3) and the envelope glycoproteins E1 and E2 are candidate immune targets for developing anti-HCV DNA vaccine. Nevertheless, the immune response elicited by these antigens often appears weak and/or transient. Different approaches have been studied for enhancing and/or modulating the immune response of the DNA vaccine. On the basis of a prototype multigenic plasmid vector constituted of two different transcription cassettes (pRC100), we have developed a plasmid vector that allows the independent and simultaneous expression of murine IL2 and of an antigenic domain of the HCV NS3 C terminus (pRC112-HCV). The highly conserved NS3 region spans from nt 4403 to nt 4829 and contains two putative B and T epitopes. The development of this multigenic plasmid vector may combine the expression and local production of an immunomodulatory molecule (mlL2) together with the possibility of addressing the host immune response to the most immunogenic and conserved epitopes, specifically tailored in the plasmid vector.

KW - B/T epitopes

KW - DNA vaccination

KW - HCV NS3

KW - Multigenic plasmid vector

KW - Murine lL2

UR - http://www.scopus.com/inward/record.url?scp=0032158323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032158323&partnerID=8YFLogxK

U2 - 10.1016/S0923-2516(99)89012-8

DO - 10.1016/S0923-2516(99)89012-8

M3 - Article

C2 - 9879611

AN - SCOPUS:0032158323

VL - 149

SP - 315

EP - 319

JO - Research in Virology

JF - Research in Virology

SN - 0923-2516

IS - 5

ER -